TR-1 notification of major interest in shares

19^th Jul 2017

Download the full announcement.

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:			EKF Diagnostics Holdings PLC (Company number 04347937 and registered office address at Avon House, 19 Stanwell Road, Penarth, Cardiff, CF64 2EZ)
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)ⁱⁱⁱ:

3. Details of person subject to the notification obligation^iv
Name			Zwanziger Family Ventures, LLC
City and country of registered office (if applicable			Boston, MA 02465, United States of America

4. Full name of shareholder(s) (if different from 3.)^v
Name
City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached^vi:

17/07/2017

6. Date on which issuer notified (DD/MM/YYYY):

18/07/2017

7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer^vii
Resulting situation on the date on which threshold was crossed or reached	4.666%			4.666%	21,661,694
Position of previous notification (if applicable)	7.98%			7.98%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^viii<
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights^ix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Ordinary Shares GB0031509804		21,661,694					4.666%
SUBTOTAL 8. A		21,661,694					4.666%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date^x	Exercise / Conversion Period^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date^x		Exercise / Conversion Period ^xi		Physical or cash settlement^xii			Number of voting rights	% of voting rights
					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer^xiii<
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity^xiv(please add additional rows as necessary)				X
Name^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
The Zwanziger Family 2012 Irrevocable Trust Trustees: Orit Goldstein and Evan Heller Settlor: Ron Zwanziger Beneficiaries: The Zwanziger family	100%		100%

10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information^xvi

Place of completion	London
Date of completion	18/07/2017

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

HbA1c testing at the point-of-care: Comparison against international quality standards

Nurses from the University of Arkansas Study Abroad program using DiaSpect Tm in Ghana

EKF at Medic East Africa - Nairobi 2018

EKF to highlight new Glycated Albumin assay kit at AACC 2018

EKF Diagnostics, the global in vitro diagnostics company, announces that on Booth #3880 at the AACC 2018 Clinical Lab Expo it will be highlighting a new Stanbio Chemistry Glycated Albumin (GA) assay kit and its newly FDA cleared DiaSpect Tm hemoglobin point of care analyzer. Located in Chicago, IL, from July 31^st to August 2^nd, AACC is the world’s largest exposition for clinical laboratory products and services.

EKF at AACC - Chicago 2018

Product showcase

Copyright © 2018 | Powered by Intergage

Quick links

News and Events

Anemia and Hemoglobin testing

Diabetes and HbA1c testing

Support

Social media

Privacy | Terms & Conditions | Terms of Sale | UK Modern Slavery Act